CoQ10 – Ayurved Healing

Mitochondrial Health and Rasayana: How Rejuvenative Herbs Protect Cellular Power Plants

Dr. Meera Iyer — Wed, 10 Jun 2026 09:00:00 +0000

Mitochondria are membrane-bound organelles that generate much of the ATP used by human cells through oxidative phosphorylation. They also participate in calcium handling, redox signaling and programmed cell death. These functions make mitochondrial biology relevant to energy metabolism, muscle performance, neurological function and many diseases. However, Ayurveda’s classical texts do not describe mitochondria, ATP, Coenzyme Q10 or molecular pathways such as PGC-1alpha.

Rasayana should therefore not be presented as an ancient name for mitochondrial medicine, and Ojas should not be equated with ATP. Rasayana is a classical Ayurvedic branch and therapeutic approach concerned with preserving health, function and longevity; its scope is broader than any organelle or supplement. Modern research can test whether particular Rasayana substances influence mitochondrial pathways, but that is a contemporary research bridge, not proof that the two systems are identical.

What Mitochondrial Health Means Clinically

In cells that contain mitochondria, the electron-transport chain transfers electrons through respiratory complexes and uses a proton gradient to make ATP. Coenzyme Q10 is a mobile lipid-soluble carrier that receives electrons from Complexes I and II and transfers them toward Complex III. Mitochondria also generate reactive oxygen species: excessive amounts may contribute to damage, while controlled amounts serve normal signaling roles.

Primary mitochondrial diseases are diverse, often genetic disorders whose manifestations vary between people and organs. Fatigue, exercise intolerance, weakness and cognitive complaints may occur, but none is specific enough to diagnose mitochondrial disease. Persistent or progressive symptoms require clinical assessment rather than self-diagnosis as “low Ojas” or “mitochondrial fatigue.”

Regular physical activity has much stronger human evidence for mitochondrial adaptation than any Ayurvedic herb. Endurance and resistance exercise can stimulate mitochondrial remodeling, including PGC-1alpha-related signaling, while improving cardiovascular and muscular fitness. Sleep, adequate nutrition and treatment of proven deficiencies are foundational; supplements should not replace investigation of common causes of fatigue.

Rasayana Herbs and the Actual Mitochondrial Evidence

The table separates human outcomes from mechanistic evidence. A result in cells, flies, mice or rats does not establish a clinically meaningful mitochondrial effect in people. Botanical identity also matters: the Ayurvedic Pharmacopoeia definition cited by the Ministry of AYUSH identifies Ashwagandha as the dried mature root of Withania somnifera, not the leaf.

Substance	Verified Evidence	Important Limit
Ashwagandha root (Withania somnifera)	Small, short human trials suggest possible benefits for stress, sleep and selected physical-performance measures. Cell and animal studies have examined mitochondrial energetics and PGC-1alpha-related signaling.	No convincing human trial has shown that Ashwagandha increases mitochondrial number or treats mitochondrial disease. Preparations and populations vary.
Purified Shilajit	A 2009 preclinical paper studied Shilajit-derived dibenzo-alpha-pyrones with CoQ10 in isolated systems and rodents. A separate 2019 trial in 63 active men studied strength retention after fatigue.	The first was not a human ATP trial; the second did not combine Shilajit with CoQ10 or measure mitochondrial biogenesis. Unpurified material may contain contaminants.
Bacopa (Bacopa monnieri)	Human trials and a meta-analysis suggest effects on selected cognitive-test outcomes. Mitochondrial and antioxidant findings are mainly preclinical.	Cognitive findings do not prove a mitochondrial mechanism. “Brahmi” may also denote Centella asiatica, so the botanical name must be stated.
Amalaki (Phyllanthus emblica, syn. Emblica officinalis)	Amalaki is used in the Rasayana tradition. A human retinal-cell laboratory model reported effects on oxidative stress, membrane potential and PGC-1alpha expression.	The cell model does not prove clinical protection of mitochondrial DNA, preservation of all respiratory complexes or superiority to synthetic vitamin C.
Guduchi (Tinospora cordifolia)	Animal research, including a rotenone-induced mouse model, has examined oxidative stress and mitochondrial dysfunction.	No human mitochondrial benefit is established. Case series and reviews link some Tinospora cordifolia products with clinically apparent liver injury.

Shilajit and the CoQ10 Question

CoQ10 cycles between oxidized and reduced forms during electron transport; calling only ubiquinol the “active” form oversimplifies this redox cycle. The frequently repeated Shilajit claim comes from a 2009 paper in Pharmacologyonline, not the Journal of Agricultural and Food Chemistry. Its experiments used isolated dibenzo-alpha-pyrones, mitochondrial preparations and small groups of rodents. One rat experiment found higher tissue CoQ with a dibenzo-alpha-pyrone plus CoQ10 than with CoQ10 alone, but it did not demonstrate a 29% improvement in human electron-transfer efficiency, ATP, fatigue or exercise capacity.

The cited 2019 human study did not test a Shilajit-CoQ10 combination. It randomized 63 recreationally active men to placebo or purified Shilajit for eight weeks and assessed strength after fatigue. The higher-dose group retained maximal voluntary isometric contraction better after a fatiguing protocol, while other findings depended on subgroup analysis. This is preliminary performance evidence, not proof of mitochondrial rejuvenation.

There is therefore no verified basis for telling everyone who takes CoQ10 to add Shilajit or for prescribing a universal dose here. Anyone considering it should consult a qualified healthcare professional and use only purified material with independent, batch-specific contaminant testing. Pregnancy, chronic disease, medicines and unexplained fatigue all require individualized advice.

PGC-1alpha and Mitochondrial Biogenesis

PGC-1alpha is an important transcriptional coactivator in mitochondrial biogenesis and energy metabolism, but it is not a solitary on-off switch. Exercise, cellular energy status and multiple signaling networks regulate mitochondrial content and function. Human exercise studies support PGC-1alpha-related adaptation, although responses vary by training status, exercise type, tissue and measurement timing.

Later cell and animal studies have explored Ashwagandha-related changes in mitochondrial function and PGC-1alpha-associated pathways. They generate hypotheses but do not establish mitochondrial biogenesis in patients or clinical synergy between Ashwagandha and exercise.

A Safer Mitochondria-Supportive Rasayana Framework

A responsible Rasayana plan begins with the person, not a five-supplement stack. Ayurvedic care is individualized, while modern care must also consider diagnosis, laboratory findings, medicines, pregnancy and organ function. The following framework is safer than fixed morning and bedtime doses.

Investigate persistent symptoms: unexplained fatigue, weakness, neurological change, exercise intolerance or multisystem symptoms should be assessed by a healthcare provider.
Use movement as the foundation: combine aerobic activity with progressive resistance work at a level appropriate to health and fitness. Begin gradually and seek clearance when symptoms or heart disease make exercise uncertain.
Correct documented deficiencies: CoQ10, magnesium or B vitamins should not be prescribed merely because fatigue is present. History, diet, medicines and testing determine whether supplementation is appropriate.
Choose one defined Ayurvedic intervention when indicated: a qualified practitioner can select the botanical, plant part, preparation and duration. This is preferable to taking Ashwagandha, Shilajit, Bacopa, Amalaki and Guduchi together.
Monitor quality and safety: use traceable products with appropriate testing, disclose supplements to clinicians and stop promptly if jaundice, dark urine, severe itching or another concerning reaction occurs.

Even when Amalaki is used in food form, a spoonful of powder has not been shown to protect mitochondrial DNA within an hour or produce measurable mitochondrial improvement in 30 days. Ashwagandha may be unsuitable during pregnancy and can interact with medicines or affect thyroid function; rare liver injury has also been reported. Guduchi deserves particular caution because liver-injury reports contradict the assumption that every traditional herb is harmless.

Mitochondria, Aging and the Limits of the Analogy

Denham Harman proposed the free-radical theory of aging in 1956 and later emphasized mitochondria in a 1972 paper. Mitochondrial damage and altered bioenergetics remain important research areas, but the idea that mitochondrial ROS is the single primary cause of aging is no longer sufficient. Reactive oxygen species can also act as signals, mitochondrial DNA has repair systems, and aging involves many interacting processes.

Rasayana can remain a valuable traditional framework for preserving function, routine, nourishment and resilience. What cannot yet be claimed is that Amalaki clinically protects human mitochondrial DNA, Shilajit restores the electron-transport chain, Ashwagandha reverses glucocorticoid uncoupling, or Bacopa prevents neuronal mitochondrial aging in people. Those conclusions go beyond the largely preclinical evidence.

For related reading, see our Ashwagandha dosage guide, Shilajit composition guide and Amla/Amalaki guide. Supplement claims should always be distinguished by whether they come from human outcomes, surrogate biomarkers or preclinical experiments.

This article is educational and does not diagnose or treat mitochondrial disease, fatigue or any chronic condition. Most herb-specific mitochondrial findings discussed here come from laboratory or animal studies. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using medicinal doses of herbs or combining them with CoQ10, medicines or other supplements. Seek medical evaluation for persistent, progressive or multisystem symptoms. Shilajit should only be used in purified, independently tested form.

Actionable tip: Begin with regular, tolerable physical activity, consistent sleep and balanced meals rather than a multi-herb “mitochondrial stack.” Build aerobic and resistance activity gradually according to your health and capacity, and investigate unexplained fatigue before adding supplements.

References

Arjuna Bark for Heart Health: The Cardioprotective Evidence

Dr. Meera Iyer — Fri, 20 Feb 2026 10:00:00 +0000

Arjuna Bark for Heart Health: What the Evidence Supports

Terminalia arjuna is a large deciduous tree of the Combretaceae family, and its stem bark is an official Ayurvedic drug. The Ayurvedic Pharmacopoeia of India identifies the bark as Arjuna, describes it as hridya—traditionally regarded as beneficial to the heart—and lists hridroga among its therapeutic uses. These traditional indications provide an Ayurvedic basis for its use, but they do not by themselves establish effectiveness for modern diagnoses such as coronary artery disease or heart failure.

Modern clinical research has examined arjuna bark in chronic stable angina, chronic heart failure, lipid abnormalities and coronary-risk markers. The human evidence is encouraging in places but remains limited by small samples, short treatment periods, older study designs and a lack of trials measuring heart attack, stroke, hospitalization or cardiovascular death. Arjuna should therefore be considered, at most, a clinician-supervised adjunct rather than a replacement for established cardiac care.

Ayurvedic Identity and Classical Profile

The Ayurvedic Pharmacopoeia of India, Part I, Volume II, gives a specific profile for Terminalia arjuna stem bark. This profile is preferable to generalized descriptions that assign additional tastes, qualities or doshic actions without a clear classical or pharmacopoeial source.

Ayurvedic Attribute	Pharmacopoeial Description
Part used	Stem bark
Rasa	Kashaya (astringent)
Guna	Ruksha (dry)
Virya	Shita (cooling)
Vipaka	Katu (pungent post-digestive effect)
Karma	Bhagnasandhanakara, Hridya, Kaphahara, Pittahara, Vrananashana and Vyangahara
Listed therapeutic uses	Includes Hridroga, Medoroga, Vrana, Kshatakshaya, Prameha, Trishna and Vyanga
Pharmacopoeial powder dose	3–6 g

The term hridya should be understood as a traditional pharmacodynamic designation, not as proof that the bark increases cardiac contractility or reverses structural heart disease. Likewise, hridroga is an Ayurvedic disease category and should not be treated as an exact synonym for every modern cardiovascular diagnosis.

Active Constituents and Mechanistic Evidence

The pharmacopoeial monograph identifies tannins as constituents of the bark. Phytochemical investigations and reviews additionally report triterpenoids, flavonoids, glycosides, sterols and polyphenolic compounds. The composition varies with plant material, extraction method and product standardization.

Constituent Class	Reported Examples	Evidence Interpretation
Triterpenoids	Arjunic acid, arjunolic acid, arjungenin	Studied mainly in laboratory and animal models involving oxidative stress and cardiovascular injury
Triterpenoid glycosides	Arjunetin and arjunglucosides	Identified phytochemically; their independent clinical contribution is not established
Flavonoids	Luteolin, arjunone, arjunolone	Associated with antioxidant and cell-signalling effects in preclinical work
Tannins and polyphenols	Gallic acid, ellagic acid and proanthocyanidin-related compounds	May contribute to antioxidant activity, but clinical outcome effects are unproven
Sterols	Beta-sitosterol	Present in the bark; no isolated clinical effect can be inferred from whole-bark trials

Preclinical studies describe antioxidant, anti-inflammatory, endothelial, platelet and myocardial effects, but these findings do not justify describing arjuna as a botanical equivalent of digoxin or any other cardiac drug. A 2015 study in stable coronary artery disease evaluated Terminalia arjuna as an adjunct and reported changes in inflammatory and immune markers; it did not test isolated arjunolic acid as a proven treatment for clinical events.

Clinical Evidence: Chronic Stable Angina

The best-known angina studies suggest possible symptom and exercise-test benefits, yet the total evidence remains too uncertain for a firm therapeutic recommendation. The most informative individual trial was short, and the later systematic review judged the underlying studies methodologically weak.

The 2002 Crossover Trial

Bharani and colleagues published a randomized, double-blind, placebo-controlled crossover study in the Indian Heart Journal in 2002 (PMID: 12086380). It enrolled 58 men with chronic stable angina and exercise-induced ischemia. Participants received arjuna bark extract 500 mg every eight hours, isosorbide mononitrate 40 mg daily and placebo for one week each, with washout periods between treatments.

Angina frequency and use of rescue isosorbide dinitrate were lower during arjuna treatment than during placebo.
Treadmill measures, including exercise duration and time to ischemic changes, improved versus placebo.
The measured clinical and treadmill outcomes did not differ significantly between arjuna and isosorbide mononitrate during the brief treatment periods.
No important adverse effect was reported during the arjuna phase.

The trial supports a short-term signal for symptom relief, not equivalence to nitrate therapy in routine practice. It included only men, lasted one week per treatment, and was not designed to assess myocardial infarction, hospitalization or survival.

The 1994 Open Study

Dwivedi and Agarwal studied bark powder for three months in 20 patients: 15 with stable angina and five with unstable angina (Journal of the Association of Physicians of India, 1994; PMID: 7741874). The stable-angina group had fewer episodes and improved treadmill findings, whereas the unstable-angina group did not show a significant reduction and required conventional antianginal medicines. Because the study was open and uncontrolled, it is supportive but not confirmatory.

The 2014 Systematic Review and Meta-analysis

Kaur and colleagues reviewed trials of arjuna in chronic stable angina (Cardiology Research and Practice, 2014; PMID: 24600529). They found poor methodological quality and no significant pooled difference for outcomes that could be meta-analyzed. Their conclusion was that the evidence was insufficient to draw a definite conclusion either for or against arjuna, and that larger, well-controlled multicenter trials were required.

Clinical Evidence: Chronic Heart Failure

Heart-failure research includes one modern randomized trial and one much smaller older study. The more rigorous trial did not improve left ventricular ejection fraction, while some secondary or post-hoc measures suggested possible functional benefit.

The 2016 Randomized Controlled Trial

Maulik and colleagues enrolled 100 patients with chronic heart failure in a double-blind randomized trial published in Phytomedicine in 2016 (PMID: 26988798). A standardized water extract of arjuna bark, 750 mg twice daily, or placebo was added to standard treatment for 12 weeks.

Arjuna did not produce a significant improvement in left ventricular ejection fraction compared with placebo.
Post-hoc analyses found greater improvement in six-minute walk distance, antioxidant measures and selected symptom-related quality-of-life domains among some participants.
Adverse-event rates were not reported as significantly different between the groups.

The study does not establish that arjuna remodels the heart or alters heart-failure prognosis. Its more favorable findings were secondary and partly post-hoc, so they should be treated as hypothesis-generating.

The 1995 Severe Heart Failure Study

Bharani, Ganguly and Bhargava evaluated 12 patients with severe refractory heart failure in an initial placebo-controlled phase, followed by open long-term use of arjuna alongside conventional treatment (International Journal of Cardiology, 1995; PMID: 7649665). Symptoms, effort tolerance, New York Heart Association class and several echocardiographic measures improved during arjuna treatment. The very small sample, older background therapy and open follow-up prevent confident conclusions about efficacy or long-term safety.

Cholesterol, Inflammation and Platelet Findings

Short clinical studies have reported changes in lipid and biological risk markers, but they do not demonstrate prevention of cardiovascular events. Mechanistic findings should not be converted into claims that arjuna has statin-like, antiplatelet-drug-like or anti-inflammatory-drug-like clinical efficacy.

In a randomized controlled trial of 105 patients with coronary heart disease, Gupta and colleagues assigned 35 participants each to placebo, vitamin E 400 units daily or arjuna bark powder 500 mg daily for 30 days (Journal of the Association of Physicians of India, 2001; PMID: 11225136). The arjuna group had mean reductions of about 9.7% in total cholesterol and 15.8% in LDL cholesterol, while lipid-peroxide levels also fell. The short duration, modest group size and absence of clinical-event outcomes mean that this result cannot substitute for evidence supporting prescribed lipid-lowering therapy.

A 2015 adjunctive study in stable coronary artery disease (PMID: 25827448) reported attenuation of selected inflammatory and immune-imbalance markers with Terminalia arjuna. A separate 2009 laboratory study using samples from healthy volunteers and patients with coronary artery disease found reduced platelet activation (PMID: 19437336). Neither study established fewer heart attacks, strokes or bleeding events.

How Arjuna Compares with Standard Cardiac Treatment

Arjuna and guideline-directed cardiovascular medicines do not have comparable evidence bases. Established therapies are selected according to diagnosis and have large randomized trials and guideline recommendations; arjuna has small studies focused mainly on symptoms, exercise tests, ejection fraction and laboratory markers.

Clinical Question	Evidence for Arjuna	Evidence for Established Care
Stable angina symptoms	One short crossover trial was positive, but the systematic review found the overall evidence inconclusive	Multiple antianginal classes are recommended according to the patient’s condition
Heart failure	No significant LVEF benefit in the 12-week randomized trial; secondary functional signals require confirmation	Guideline-directed therapies reduce hospitalization and mortality in eligible patients
LDL cholesterol	A 30-day study reported a modest reduction	Statins and other indicated lipid-lowering drugs have cardiovascular-outcome evidence
Prevention of heart attack or stroke	Adequate clinical-outcome trials have not been conducted	Therapy is based on risk, diagnosis and evidence-based preventive medicines
Long-term safety	Not adequately established	Drug-specific risks are defined through larger trials, surveillance and monitoring guidance

Medical Disclaimer: Do not replace beta-blockers, nitrates, antiplatelet medicines, anticoagulants, statins, ACE inhibitors, ARBs, ARNIs, mineralocorticoid antagonists, SGLT2 inhibitors or any other prescribed cardiac treatment with arjuna. Discuss any arjuna product with a cardiologist and a qualified Ayurvedic practitioner. New, severe or worsening chest pain, breathlessness, fainting or symptoms occurring at rest require urgent medical assessment.

Dosage, Traditional Preparation and Safety

Arjuna bark powder, milk decoctions and commercial extracts are not interchangeable. Their concentrations and chemical profiles differ, and the dose used in a clinical trial applies only to the tested preparation. Self-treatment is particularly inappropriate for anyone with diagnosed heart disease or multiple medicines.

Ayurvedic Dose and Arjuna Ksheerapaka

The Ayurvedic Pharmacopoeia of India lists 3–6 g of stem-bark powder. Arjuna ksheerapaka, a milk-based preparation, is taught in Ayurvedic pharmaceutics, but published descriptions document more than one textual method and more than one bark-to-milk-to-water ratio. A single household recipe should therefore not be presented as universally classical. Preparation, dose, timing and suitability should be determined by a qualified practitioner, especially for people who must restrict fluid, sodium, potassium, sugar or dairy intake.

Clinical-Trial Doses

The angina crossover trial used 500 mg of bark extract every eight hours for one week, while the heart-failure trial used 750 mg of standardized water extract twice daily for 12 weeks. These regimens do not establish a general-purpose supplement dose, and products that do not match the trial extracts cannot be assumed to produce the same effects.

Safety and Interaction Considerations

Small trials generally describe arjuna as reasonably tolerated over their study periods, but this is not proof of long-term safety. Reviews have repeatedly noted limited safety data and inadequate standardization across preparations.

Antiplatelet or anticoagulant treatment: Laboratory evidence of reduced platelet activation creates a plausible interaction concern, although clinical bleeding risk has not been established. A prescriber should review combined use with aspirin, clopidogrel, warfarin, direct oral anticoagulants or similar medicines.
Blood-pressure and heart medicines: Preclinical cardiovascular effects and use alongside multiple cardiac drugs justify monitoring rather than assuming compatibility.
Thyroid disease: An animal study reported changes in thyroid hormones during arjuna exposure. A human interaction with levothyroxine or antithyroid treatment has not been established, so clinician review is appropriate.
Product quality: Use authenticated stem-bark products made under appropriate quality standards. Avoid unlabeled powders, proprietary mixtures with undisclosed quantities and products making claims to replace prescribed treatment.
Follow-up: Blood pressure, symptoms and relevant laboratory tests should be monitored according to the person’s diagnosis and medication regimen.

Where the Evidence Stands

Arjuna has a verified place in Ayurvedic materia medica: the pharmacopoeial bark is kashaya in rasa, ruksha in guna, shita in virya and katu in vipaka, with hridya, kaphahara and pittahara among its listed actions and hridroga among its uses. Its modern cardiovascular evidence, however, is not strong enough to support routine substitution for proven treatment.

The most defensible interpretation is that arjuna is a research-worthy adjunct. A short angina trial found symptomatic and treadmill benefits, but the systematic review was inconclusive. The principal heart-failure trial did not improve ejection fraction. A short lipid trial reported moderate biochemical changes, while anti-inflammatory and platelet findings remain surrogate or laboratory evidence.

Future trials need standardized, chemically characterized preparations; adequate sample sizes; longer follow-up; transparent adverse-event reporting; and hard outcomes such as myocardial infarction, stroke, heart-failure hospitalization and cardiovascular mortality. Until such data exist, arjuna should be used only within coordinated care from a qualified Ayurvedic practitioner and the patient’s healthcare provider.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.